a.
Tache noir
Tache noir is a skin condition that occurs at the posterior edge. It can manifest itself on the surface of either heels or one. It is significant since it shows the early signs of postmortem ocular. For example, the condition aid in autopsy during the medical examination to find the cause of death.
b.
Tardieu spot
This is critical in assisting to establish if the death person was strangled or asphyxiated. It is significant during autopsy as it displays the tissues of the person and indicates if they were squeezed on pressed hard causing death. For example, it is a determination factor in the case of suffocation of ecchymosis (Kriminol, 2010).
c.
Petechiae
It is purple or red spot found in the skin. It occurs via trauma, for example, holding breath, hard bout, crying or vomiting. They harmless and may disappear after some time. They are significant during autopsy since it is easy to establish the cause of bleeding or in the case of a broken blood capillary. It is further significant to children since they show the potentiality of serious illness. If they stay for long after 48 hours, it may cause death.
d.
Mongolian spots
It is a congenital condition. It is significant in the determination if the person has sustained bruises or it is Mongolian spots. During the autopsy, the doctor can rule out abuse if it is determined, that it is Mongolian spots. The multiple spots are located in the lumbosacral area, buttocks and shoulders. The condition concerns the skin. It turns blue or grey caused by melanocytes (Mongolian spot, 2004).
e.
Battle signs
It is significant in the indication of fracture of the cranial fossa of the individual’s skull. Help in checking the existence of the brain trauma. During the autopsy, bruises are check due to extroversion, for example, checking blood at the posterior auricular artery. Further, raccon eyes can be noticed at the back of the ear.
References
Kriminol, A. (2010). Tardieu's spots and asphyxia--a literature study. NCBI, 226(5-6), 145-60.
Mongolian spot. (2004). Dermatology Therapy, 392-393. doi:10.1007/3-540-29668-9_1800
